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Tetrahydropyrimidines are a class of azaheterocycles, also called Biginelli hybrids (obtained from the
Biginelli reaction), that have attracted an enormous interest in the medicinal chemistry community in
recent years, due to a broad biological activity, such as anticancer, antiviral, anti-inflammatory,
antidiabetic, antituberculosis activities, etc. According to SciFinder®, more than 70 000 different
Biginelli-like compounds have been covered in publications. However, although the Biginelli reaction
can yield a large number of compounds with a broad range of activities, none of them have been
captured in a carrier. In this study, chitosan-based (Ch) nanoparticles (NPs) containing three different
molecules (Biginelli hybrids) were developed and tested for the first time as simple and promising
vehicles for anticancer Biginelli-based drugs. The key features of NPs, such as size, surface morphology,
drug encapsulation efficiency, and in vitro release were systematically investigated. Rather weak cell
selectivity of pure Biginelli hybrids (A–C) to selected cancer cell lines has improved and this has been
accompanied with two-to-four times stronger cytotoxic effect of A–C loaded Ch NPs, with a triple
reduction in toxicity to healthy cells (MRC-5). It has been observed that the examined NPs induce
apoptosis. The cell cycle analysis has confirmed the influence of A-loaded Ch (A-Ch), B-loaded Ch (B-
Ch), and C-loaded Ch (C-Ch) on the cell cycle distribution, which was homogenously affected. This is
the difference with regard to the effect of A, B, and C on the cell cycle. It has been established that the
increased selectivity and antitumor activity of NPs are related to the presence of the carrier.Introduction
The Biginelli reaction was developed by Pietro Biginelli in 1893.
In this acid-catalysed one-pot synthesis, aldehyde, b-ketoester
and urea(thiourea) participate in the development of
tetrahydrpyrimidines-THPMs (formerly known as 3,4-dihy-
dropyrimidin-2(1H)-ones). This class of compounds are partic-
ularly interesting in pharmaceutical sciences due to the
biological activity associated with their heterocyclic structure.
THPMs have been used therapeutically as calcium channel
modulators (e.g. nifedipine, nicardipine and amlodipine), asand Clinical Pharmacology, Faculty of
ia, Pasterova 14, 11000, Belgrade, Serbia
ian Academy of Science and Arts, Knez
lgrade, Serbia. E-mail: nenad.jankovic@
ujevac, Department of Science, University
gujevac, Serbia
tion (ESI) available. See DOI:
1550well as a1-adrenergic receptor antagonists (e.g. terazosin and
niguldipine).1–3 The anticancer activity of THPMs is based on
their ability to interrupt the cell cycle during mitosis. The
molecules that perturb microtubule depolymerization or poly-
merization block the cell cycle in mitosis by disturbing the
normal microtubule dynamics. Several drugs that bind to
tubulin and inhibit spindle assembly may be cited as examples,
e.g. paclitaxel and docetaxel, as well as vinca and colchicine
analogues. The rst THPM identied as a mitotic kinesin
inhibitor was monastrol, in 1999. Since then, many THPMs
have been synthesized and tested as potential Eg5 inhibitors.3,4
Despite the apparent advances in therapy development over
the last decades, cancer is still the second leading cause of
death globally. With millions of deaths each year, lung, pros-
tate, colorectal, stomach and liver cancer are the most common
types of cancer in men, while breast, colorectal, lung, cervical
and thyroid cancer are the most represented among women.
Cancer therapy nowadays includes several different approaches,
including surgery, chemotherapy, radiation therapy, immuno-
therapy, and targeted therapy. It is very common that different
approaches are combined to achieve the best therapeuticThis journal is © The Royal Society of Chemistry 2020
Scheme 1 Synthetic route towards THPMs (A–C); A: R1 ¼ OMe, R2 ¼




































































































View Article Onlineoutcome. Many cancer types are usually associated with
reduced long-term survival and an unsatisfactory quality of life.
However, a sufficiently effective therapy has not yet been
developed and innovative drug delivery is considered as one of
the ways to improve the existing therapy.5–8
Recent decades have witnessed an exceptional growth of
research in nanotechnology. Nanoparticles (NPs) are widely
studied products in medicine due to their nanoscale sizes and
comparatively large surfaces, as well as their capacity to interact
with different biological systems more efficiently with a better
therapeutic outcome. Also, due to their ability to adsorb and
carry other molecules, they are relevant for the transport and
release of different drugs, probes, and proteins. One of themain
issues in nanotechnology is to select appropriate carriers
meeting specic requirements regarding incorporation and
release, stability, biocompatibility, biodistribution, and
possible adverse effects.9–13
Biodegradable polymers are very suitable for drug formula-
tions as they do not require any elimination pathway from
human body. One of the most used materials for this purpose is
chitosan (Ch). Its biocompatibility and mechanical properties
make it a very convenient candidate for nanoformulations. Ch
is a polysaccharide consisting of glucosamine and N-acetylglu-
cosamine units. The protonation of amine groups in glucos-
amine units requires slightly acidic pH. As a result, the whole
molecule has cationic properties, enabling interactions with
different anionic structures, such as cell membranes, nucleic
acids, and macromolecules. Drug release from Ch-based
systems primarily depends on the physicochemical character-
istics of the incorporated drugs. The mechanisms that could be
involved in drug release of Ch-based dosage forms include: (1)
diffusion, (2) swelling, (3) erosion and (4) biodegradation. In
recent years, Ch has been extensively exploited as a cationic
polymer material in the delivery of anticancer drugs. Fast
degradation and intensive swelling in aqueous solutions could
lead to rapid drug release. Consequently, in the development of
sustained drug release systems, physical and chemical modi-
cations of chitosan are required in order to improve the stability
of formulations in neutral or alkaline environments.14–17
Our previous research, highlights that anticancer drugs
based on anticancer compounds loaded into nanoparticles of
bioresorbable polymers have improved features.18–20 With an
improved understanding of nanomaterials and the application
of nanotechnology our strategies are currently being directed
towards improving the ability of anticancer nanostructures to
target specic tissues and to reduce the toxicity of pure
compounds by coating them with appropriate nanocarriers.
According to SciFinder®, in July 2020, more than 70 000
different Biginelli-like compounds have been published. So far,
many potential Biginelli-based drugs have failed in clinical
trials due to poor water solubility and, consequently, poor
bioavailability, the lack of selectivity, toxicity, and stability
under physiological conditions. However, although the Biginelli
reaction yields a huge number of compounds with a broad
range of activities, none of them were captured in a carrier.
Given the above considerations, our combined interest in
sustainable, green and Biginelli chemistry,21–27 has inspired usThis journal is © The Royal Society of Chemistry 2020to develop specic sustainable formulations with fast delivery
and improved cytotoxic selectivity of the selected Bignelli
hybrids in targeting cancer cell lines.
In this research, we have investigated for the rst time
spherical nanoparticles made of Ch and loaded with three
different THPMs (Scheme 1 and Fig. 1): ethyl 6-(chloromethyl)-
4-(4-hydroxy-3-methoxyphenyl)-1-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (A), ethyl 4-[4-(benzyloxy)
phenyl]-6-(chloromethyl)-1-methyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (B) and ethyl 6-
(chloromethyl)-4-(4-hydroxy-3-iodo-5-methoxyphenyl)-1-methyl-
2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (C).
As shown in Fig. 1, the difference between A, B and C can be
observed at the C-4 position in the THPM scaffold which
consists of the following aryl substituents: 40-hydroxy-30-
methoxyphenyl (A), 40-benzyloxyphenyl (B), and 40-hydroxy-30-
iodo-50-methoxyphenyl (C). The chemical structure of A, B and C
is conrmed by 1H and 13C NMR spectra (ESI, Fig. S1–S6†). The
content of compounds in chitosan nanoparticles (Ch NPs) was
measured using HPLC.
Attenuated total reectance Fourier transform infrared (ATR-
FTIR) spectroscopy was applied to measure surface properties.
Compound loading process was monitored by simultaneous
thermogravimetric/differential thermal analyses (TGA/DTA),
while scanning electron microscopy (SEM) was employed in
the analysis of the morphology of NPs. Drug release tests were
performed using high performance liquid chromatography
(HPLC) to measure the rate of A, B and C release from NPs. The
selective viability effect of the THP derivatives and the obtained
NPs was examined using MTT assays on the four different cell
lines: cervical cancer cells (HeLa), colorectal adenocarcinoma,
(LS-174), human lung carcinoma (A549) and human lung
broblasts (MRC-5). Flow cytometry was used for assessing the
cell cycle, to measure cellular DNA content.Results and discussion
In this study, free A, B and C Biginelli derivatives were encap-
sulated for the rst time into the framework of Ch according to
the described method. The encapsulation process was
conrmed by FTIR. Fig. 2 shows the FTIR spectra of Ch, THPMs
(A, B and C) and their appropriate nanoparticulate derivatives
(A-loaded Ch, B-loaded Ch and C-loaded Ch) in the frequencyRSC Adv., 2020, 10, 41542–41550 | 41543
Fig. 1 Structures of Biginelli hybrids A–C.
Fig. 2 FTIR spectra of (a) Ch, (b) A, (c) A-Ch, (d) B, (e) B-Ch, (f)C and (g)
C-Ch.



































































































View Article Onlinerange from 4000 to 400 cm1. The FTIR spectra of the pure
Biginelli hybrids A, B and C (Fig. 2b, d and f) show peaks near at:
3300 cm1 – assigned to the N–H stretching vibrations,
3200 cm1 – due to the C–H stretching vibrations, 1628 cm1 –
due to the C–N stretching vibrations, 1070 cm1 – attributed to
the C–O–C stretching vibrations, and 936 cm1 – due to the C–H
deformation. The sharp band between 1700 and 1600 cm1 in
the spectra of derivative A, B and C, originates from the vibra-
tion of the carbonyl group. This characteristic band is also
present in the FTIR spectra of the A-loaded Ch (A-Ch), B-loaded
Ch (B-Ch) and C-loaded Ch (C-Ch) samples (Fig. 2c, e and g).
In the FTIR spectrum of Ch, characteristic absorption bands
appear at 1655 cm1, which can be attributed to both the C]O
stretching vibrations and an amide I band, and at 1580 cm1,
attributed to amide II band. The bands near 1066 cm1 and
1028 cm1 correspond to the C–O stretching vibrations. All
bands are also found in the chitosan spectra reported by
others.19,28 The appearance of bands characteristic for pure
Biginelli derivatives A, B and C in the spectra of the A-Ch and B-
Ch and C-Ch systems may be indicative of Biginelli pyrimidines
entrapped in Ch during the synthesis of NPs. Furthermore, an
increased intensity of the C–H band near 3200 cm1 in the
spectra of the A-Ch, B-Ch and C-Ch systems as compared to the
spectra of pure A, B and C, respectively, is probably due to
hydrogen bonding between A, B and C Biginelli derivatives and
Ch.
Thermogravimetric analysis (TGA) is applied to determine
the mass loss of the sample over time according to temperature41544 | RSC Adv., 2020, 10, 41542–41550changes. TGA and DTA are suitable methods for analyzing and
identifying the chemical composition of nanomaterials by
investigating the thermal performance of a substance as it is
heated.29
The TGA and DTA of Ch, A, A-Ch, B, B-Ch, C, and C-Ch in the
30–700 C temperature range are shown in Fig. 3. A moderate
weight loss in Ch (Fig. 3a) at about 250 C is associated with the
loss of adsorbed water. This phenomenon is conrmed by
a broad endothermic peak of the DTA curve at 100 C (Fig. 3a).
In the 250–700 C interval, the region extending from 250 C to
300 C stands out with a drastic weight decrease: from 88% to
58%. It is followed by the region from 300 C to 630 C, where
weight loss ranging from 58% to 2% is observed. The thermal
degradation of chitosan is a two-step process entailed by chain
scission and depolymerization reactions,30 which could also be
conrmed by the double wide exothermic peak with peaks at
300 and 482 C. The DTA curve of compound A (Fig. 3b) shows
two endothermic peaks, at 120 C and 165 C, due to water loss
and melting, respectively, while a wide exothermic peak in the
200–600 C range, with the maximum at 483 C, probably
originated from the thermal decomposition of compound A.
The total weight loss (100%) of compound A was observed at
581 C. As it can be seen in Fig. 3c, the DTA curve of A-loaded Ch
is dominated by peaks characteristic for compound A and Ch.
As opposed to the DTA curve of compound A, the thermal
decomposition of compound B was characterized by broad
exothermic peaks with a maximum at 474 C (Fig. 3c). The
complete decomposition of compound B (total weight loss,
100% at 610 C) is marked by broad exothermic peaks of the
DTA curve (Fig. 3d) with a maximum at 546 C. A broadCh.
This journal is © The Royal Society of Chemistry 2020
Fig. 5 Comparative cumulative curves of the release of A, B and C in



































































































View Article Onlineexothermic peak with a maximum at 486 C (Fig. 3e) is char-
acteristic of the thermal decomposition of B-loaded Ch.
Compound C decomposes completely at 576 C (Fig. 3f) with
a characteristic exothermic maximum of the DTA curves at
503 C. The presented DTA curve of C-loaded Ch (Fig. 3g) is
marked by a broad endothermic peak at 488 C.
Based on the results shown in Fig. 3, it is possible to observe
shis between the maxima in the DTA curves of pure
compounds A, B, C and compound-loaded Ch (Fig. 3b–g). These
shis are the evidence of a compound–chitosan interaction,
which is most likely due to hydrogen bonding between Ch and
compound. In general, a drug–chitosan interaction in drug-
loaded chitosan particles results in a shi of the maximum or
minimum in the DTA and DSC curves.31,32
SEM is routinely applied to generate high-resolution
images of the morphology of different materials. In nano-
technology, it has been employed to resolve important ques-
tions regarding particle size, shape, chemical composition,
crystalline structure and texture. The morphology of A-Ch, B-
Ch and C-Ch powders is shown in Fig. 4. The encapsulation of
A, B and C into Ch leads to the formation of particles with
a spherical morphology. Aer the synthesis of A-Ch, B-Ch and
C-Ch (experimental section), the particles were processed in
a centrifugal eld (21 000 rpm), implying that spherical
morphologies were expected. In our previous research, pro-
cessing in the strong centrifugal eld also caused the forma-
tion of spherical morphology of polymer particles.33 The
obtained particles were not agglomerated; however, particle
size distributions were not uniform. The morphological anal-
ysis reveals two size distributions in all particle types: larger
particles with an average diameter of 100  20 nm and smaller
ones with an average diameter of 30  10 nm. The possibility
of obtaining bimodal proles of particle size distributions
aer using emulsication–evaporation method has been
highlighted in the literature.34–36 Homogeneous and hetero-
geneous binary colloidal clusters can be formed by self-
assembly evaporation within droplets.34 During emulsica-
tion and high energy mixing at 21 000 rpm, the self-assembly
of Biginelli compounds is possible, which leads to the
formation of two size distributions.
To gain deeper insights into bioavailability and to measure
drug release kinetics, measurements using HPLC were per-
formed. The areas of released compounds (A retention time of
22.5 min; B retention time of 41.6 min and C retention time of
32.4 min) in HPLC chromatograms were compared and the
concentrations of the released compounds were calculated.
The results are presented in the form of a cumulative curve
in Fig. 5. Over 50% of pure compounds were released in the rstFig. 4 SEM micrographs of (a) A-Ch, (b) B-Ch, and (c) C-Ch.
This journal is © The Royal Society of Chemistry 20206 h; in 48 h around 80% were released. Keeping in mind that Ch
with a medium molecular weight was used as the carrier in the
formulations, these ndings are not surprising. Moreover, the
complete release of the Biginelli hybrids was observed aer the
third day, i.e. 8.5%; 88.7% and 88.45% of A, B and C respec-
tively. Drug encapsulation efficiency was also measured using
the HPLC technique. It was conrmed that encapsulation effi-
ciency was 90%. The ratio of Biginelli hybrids and chitosan was
20 : 80, since the efficiency was 90%, the share of entrapped A,
B, and C was 18 wt%.
In addition, to estimate the amount of the drug (A, B or C)
present on the surface of the NPs, detected based on the
immediate release aer dissolution in appropriate media,
a Loose Surface Crystal Study was performed. The experimental
data conrm that compounds A, B and C are present on the
surface of NPs in concentrations smaller than 5%. Also, the
drug entrapment efficiency study shows that in the rst 24 h
72.32%, 70.4% and 71.2% of A, B and C respectively were
released (Table 1).
Table 2 shows the cytotoxic values of pure derivatives A, B, C
and their NPs on selected cell lines: cervix adenocarcinoma
(HeLa), human colorectal adenocarcinoma, (LS-174), lung
cancer cells (A549) and human broblasts (MRC-5). It has been
observed that for tumor cells IC50, the values for pure deriva-
tives A, B and C are higher or, in some cases, practically the
same as those for the corresponding NPs derivatives (A-Ch, B-
Ch, and C-Ch). Ch is a biologically inert material, and it does
not exhibit cytotoxic effects. Therefore, it can be concluded that
higher cytotoxicity values can only be a consequence of the
action of NPs. There are numerous examples demonstrating
how different technological operations can change the effects of
active pharmaceutical ingredients in appropriate drugs.18–20 InTable 1 Results of loose surface and drug entrapment efficiency
studies




RSC Adv., 2020, 10, 41542–41550 | 41545
Table 2 Concentrations of investigated pure derivatives A, B, C and




HeLa A549 LS174 MRC-5
Ch carrier 882  14 nd nd 830  30
A-Ch 2.92  0.21 5.28  0.01 4.3  0.02 3.70  0.75
B-Ch 5.97  0.14 5.76  0.25 5.86  0.01 8.90  0.14
C-Ch 5.61  0.13 5.94  0.05 5.78  0.18 11.74  0.13
A 9.53  0.15 10.42  0.92 10.31  0.54 4.3  0.10
B 5.00  0.30 6.72  0.32 7.12  0.36 3.22  0.05
C 5.05  0.21 8.39  0.02 4.71  0.12 2.56  0.03
a From three independent experiments.
Fig. 6 Control – negative control group (normal cells): circular nuclei
are uniformly distributed in the cells. Images A-Ch, B-Ch, C-Ch show
experimental groups (apoptotic cells) after the treatment with the
corresponding NPs. Green fluorescence from acridine orange staining,
which is present in crescent-like or granular form, can be observed in
the nuclei. Arrows indicate apoptotic cells with fragmented nuclei,



































































































View Article Onlinethis case, the incorporation of A, B and C in NPs resulted not
only in greater cytotoxicity but also in greater selectivity in
action toward tumor than normal cells. In the MRC-5 cell line,
which is a healthy human cell line, it has been observed that
stronger cytotoxic effects are caused by pure hybrids than by
appropriate NPs. Only in case of pure hybrid A, the IC50 value is
higher than that in the corresponding NPs system (A-Ch).
Apoptosis is a form of programmed cell death regulated by
specic genes and it has a role in the elimination of physio-
logically redundant, physically damaged, and abnormal cells.
By employing acridine orange/ethidium bromide uorescent
staining, it is possible to detect apoptosis-associated changes of
cellular nuclei.
Fig. 6 shows the results of experiments without the NPs and
aer the treatment with the selected NPs. In the control group,
no signicant apoptosis was detected, but cells in late stages of
apoptosis, marked by crescent-shaped or granular green stain-
ing, were observed aer the treatment with NPs systems in the
experimental groups. It is noteworthy that in experimental
groups, staining was localized asymmetrically within the cells,
whereas in normal cells, it was symmetrically deployed. To
examine the mechanisms of action of the tested NPs in HeLa
cells in greater detail, the cell cycle distribution was
determined.
As shown in Fig. 7, 24 hours aer exposure to nanoparticles,
the number of HeLa cells in the G1 phase increased moderately
for all tested compounds. Also, sub-G1 fraction increased for
cells treated with any of the studied nanoparticles. The accu-
mulation of cells in the G1 phase and the increased number of
cells in the sub-G1 phase is accompanied with a decrease in the
proportion of cells in the G2/M and S phases, compared to the
control, untreated HeLa cells. Apoptosis in HeLa cells was
conrmed, and the distribution of the cell cycle was homoge-
neous, which was not the case when compounds A, B and C
were free.
During the testing of the pure hybrids (A, B and C),
apoptosis was also conrmed, but the distribution of the cell
cycle was non-homogeneous, conrming that the presence of
the drug carrier did not only contribute to the activity and41546 | RSC Adv., 2020, 10, 41542–41550selectivity of Biginelli hybrids, but it also signicantly affected
the cell cycle.Experimental
Synthesis of A, B and C
To 1.5 mmol of N-methylurea in a 5 mL round-bottom ask,
a mixture of ethyl-4-chloroacetoacetate (1 mmol) and aldehyde
(1 mmol of vanillin, p-benzyloxybenzaldehyde, and 5-iodo-
vanillin for synthesis of A, B and C, respectively) was added
and aer that, 0.5 g PEG-1000 and two drops of HCl (36.5%)
were added at 70 C. Two hours later, a 70% ethanol–water
solution (10mL) was added into the reactionmixture and boiled
for 0.5 h. Aer cooling in a refrigerator, the desired products
were crystalized, ltrated, and washed with a cooled 70%
ethanol–water solution.This journal is © The Royal Society of Chemistry 2020
Fig. 7 Cell cycle distribution after 24 h, continuous action of investi-
gated NPs (A-Ch, B-Ch and C-Ch). After exposure for 24 h (the
concentration corresponded to the IC50 value obtained in the MTT



































































































View Article OnlineSynthesis of A-loaded Ch (A-Ch), B-loaded Ch (B-Ch) and C-
loaded Ch (C-Ch)
Chitosan (Ch) with a medium molecular weight (Sigma-Aldrich,
deacetylation > 80%), dissolved in acetic acid (1 wt%), wasmixed
with an ethanol solution of A (B or C) in the Ch : A (B or C)¼ 8 : 2
weight ratio, while stirring with a magnetic stirrer at 400 rpm.
The obtained mixture of A (or B or C), and Ch was slowly poured
into a sodium triphosphate pentabasic solution (STP, Sigma-
Aldrich) 0.1 wt% in H2O, while stirring at 21 000 rpm for
30 min. The obtained mixture was then centrifuged at 5000 rpm
and 5 C for 1 h, and the resulting precipitate was subjected to
lyophilization at temperatures ranging from 10 to 60 C and
pressures ranging from 0.37 mbar to 0.1 mbar for 1 h to 8 h. The
obtained powder was washed with distilled water three times,
centrifuged at 1000 rpm and dried again. The nal products
were powders composed of A-Ch, B-Ch and C-Ch particles.Characterization of the products
The NMR spectra of the compounds A–C (ESI, Fig. S1–S6†) were
recorded in CDCl3 or DMSO-d6, with TMS as the internal stan-
dard on a Varian Gemini 200MHz NMR spectrometer (1H at 200
and 13C at 50 MHz). Fourier transform infrared spectroscopy
(FT-IR) was performed on a Nicolet iS10 FT-IR Spectrometer
equipped with an attenuated total reectance (ATR) accessory in
the spectral range from 400 to 4000 cm1.
Thermogravimetric and differential thermal analysis (TG-
DTA) was performed on a simultaneous TG-DTA (Setsys,
SETARAM Instrumentation, Caluire, France) coupled with
a mass spectrometric (MS) gas analyzer (Omni Star, Pfeiffer).
About 10 mg of the samples were analyzed in the 28–700 C
temperature range under the air ow of 20 mL min1, in an
Al2O3 pan. The heating prole was set as follows: the material
was stabilized at 28 C for 5 min, and then heated to 700 C with
the heating rate of 10 min1.This journal is © The Royal Society of Chemistry 2020Field Emission Scanning Electron Microscopy (FE-SEM) was
performed on a Carl Zeiss ULTRA Plus microscope at the elec-
tron acceleration voltage of 3 kV.
Drug release
High-performance liquid chromatography (HPLC) was applied
to measure the encapsulation efficiency of the Biginelli hybrids
(A, B and C) and the in vitro drug release prole. Solutions of all
three systems were prepared in PBS in a concentration of 1 mg
mL1 and in the presence of 0.1 wt% sodium lauryl sulfate
(SLS). To estimate the release of pure A, B or C at different time
points, all measurements were carried out in triplicate at 37 C.
An Agilent 1100 Series system with a diode array detector was
used for the analysis and ZORBAX Rx-SIL (4.6 mm  250 mm, 5
mm) column was employed for separation. The mobile phase
consisted of water and acetonitrile and the estimated ow rate
was 0.5 mL min1. Gradient elution was performed in the
following way: 0–5 min with 20% of the acetonitrile, 5–25 min
20–100% gradient of the acetonitrile. The detection of pure
products was performed using a UV detector at the wavelength
of 254 nm.
The concentrations of free A, B and C were calculated using
the equation:
CTHPM (%) ¼ [(ATHPM  Vstandard  Cstandard)/(Astandard 
VTHPM  CTHPM)]  100
ATHPM and Astandard (mAU  min) is the area of the released
THPM (A, B or C) and standard (pure A, B or C which serve as
standard) in HPLC chromatograms, VTHPM and Vstandard are the
injection volumes of A, B or C and standard solutions, respec-
tively, and CTHPM and Cstandard are the concentrations of A, B or
C and the standard solutions, respectively.
Drug entrapment efficiency
The nanoparticulate formulation systems were suspended in
PBS in a concentration of 1 mg mL1 each and kept for 24 h at
room temperature. Aer 24 h solutions were stirred for 5 min
and ltered. The encapsulation efficiency of the formulated NPs
was measured spectrophotometrically at 254 nm using a Shi-
madzu UV spectrophotometer. The values were calculated in
percentages using the following equation:
Percentage of drug entrapment efficiency ¼ (actual drug content/
theoretical drug content)  100
Loose surface crystal study (LSC)
In order to estimate the amount of drug present on the surface
of NPs and amount instantly released upon suspension of NPs
in the dissolution media, a loose surface crystal study was
performed. Suspension solutions of the three NPs systems were
prepared in a concentration of 1 mg mL1 and then shaken for
15 minutes vigorously. The amount of drug released from the



































































































View Article OnlineLSC values were calculated as the percentage of drug released
with respect to entrapped drug.
Cell cultures
The cytotoxicity studies of the three nanoparticulate systems
were performed using four cell lines: human cervix adenocar-
cinoma (HeLa ATCC CCL-2) human colorectal adenocarcinoma,
(LS-174 ATCC CL-188), human lung carcinoma (A549 ATCC
CCL-185) and normal human lung broblasts (MRC-5 ATCC
CCL-171). Cells were grown to conuence in a nutrient medium
(RPMI-1640 without phenol red) supplemented with 3 mM L-
glutamine, 100 mg mL1 streptomycin, 100 IU mL1 penicillin,
10% heat inactivated fetal bovine serum (FBS), and 25 mM
Hepes, adjusted to pH 7.2 by a bicarbonate solution. RPMI-
1640, FBS, Hepes, and L-glutamine were products of Sigma
Chemical Co., St. Louis, MO. Cell cultures were maintained
under standard conditions: at a temperature of 37 C, in in
humidied air atmosphere with 5% CO2 and were passaged
twice a week. For the experiments, cells between the third and
tenth passages were used.
MTT assay
Cell viability was investigated using a MTT assay. Stock solu-
tions of the NPs (10 mg mL1 of active constituent) and pure
Biginelli pyrimidines (20 mg mL1), were prepared in DMSO
and then dissolved in a corresponding medium to achieve
adequate working concentrations. The nal concentration of
the DMSO solvent never exceeded 0.5%, a concentration
considered non-toxic to the cells. HeLa (2500 cells per well),
LS-174 (7000 cells per well), A549 (5000 cells per well), and
MRC-5 (5000 cells per well) were seeded into 96-well microtiter
plates. Twenty hours later, aer the cell adherence, ve
different concentrations of the investigated compounds in
a complete nutrient medium were added to the wells, except
for the control cells, to which only the nutrient medium was
added. Cell survival was determined by a MTT test according
to the method of Mosmann,37 as modied by Ohno and Abe,38
72 h aer the addition of the drug. Briey, 20 mL of MTT
solution [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, 5 mg mL1 in phosphate buffered saline] was
added to each well. The samples were incubated for further
four hours at 37 C in humidied atmosphere with 5% CO2.
Then, 100 mL of 10% SDS was added to the wells. Absorbance
was measured at 570 nm the following day on a microtiter
plate reader (Multiscan Ascent, Thermo Labsystems). To
calculate cell survival, absorbance at 570 nm of the sample
with the cells grown in the presence of various concentrations
of nanoparticles was divided with the absorbance of the
control sample (the absorbance of cells grown only in the
nutrient medium), implying that the absorbance of the blank
was always subtracted from the absorbance of the corre-
sponding sample with the target cells.
Morphological analysis of HeLa cells death
In order to determine the mode of the HeLa cell death induced
by the investigated compounds, a morphological analysis using41548 | RSC Adv., 2020, 10, 41542–41550the microscopic examination of acridine orange and ethidium
bromide stained cells was performed. HeLa cells were seeded
overnight on coverslips (5  104 cells) in 3 mL of the complete
medium, and on the following day, they were treated with the
investigated compounds for 24 h. The concentrations applied
corresponded to double IC50 concentrations of the investigated
NPs. The cells were subsequently stained with 6 mL of DNA dyes
acridine orange and ethidium bromide (3 mg mL1 AO and
10 mg mL1 EB in 2% solution of ethanol in water) and visu-
alized under a uorescence microscope using a uorescein
isothiocyanate (FITC) lter set. Typically, the morphological
features of the apoptotic cells were highly condensed and/or
fragmented nuclei stained with DNA dyes. In the rst phase
of late apoptosis only acridine orange entered the cell but
ethidium bromide was excluded, and the nucleus was stained
green. In the second phase of late apoptosis, along with the loss
of membrane integrity, both dyes entered the cell and the
nucleus became orange-red.
Cell cycle determination
Aliquots of 5  105 control or the cells treated with NPs for 24 h
were xed in 70% ethanol on ice for one week and centrifuged.
The applied concentrations of NPs corresponded to the IC50
values obtained in the MTT test aer incubation for 72 h. The
pellet was treated with RNase A (100 mg mL1) at 37 C for
30 min and then incubated with 40 mg mL1 propidium iodide
(PI) for at least 30 min. The cells were analyzed using a FACS-
Calibur ow cytometer (BD Biosciences Franklin Lakes, NJ,
USA) equipped with a 15 mW, air-cooled 488 nm argon ion laser
for the excitation of PI. PI uorescence (FL2) was collected aer
passing a 585/42 nm band pass lter. The FACSCalibur ow
cytometer was equipped with an FL2 upgraded doublet
discrimination module (DDM), which allows to screen and then
exclude possible occurrences of cell doublets, clumps and
debris by plotting FL2-area versus FL2-width signals,39 PI uo-
rescence data were collected using linear amplication. A
minimum of 10 000 events were collected on each sample.
Finally, data were analyzed using the FlowJo™ Soware (for
Windows, Version 10.3. Ashland, OR: Becton, Dickinson and
Company; 2019).
Statistical analysis
Results are expressed as the mean  standard deviation. All
experiments were performed in triplicate and the data were
calculated by Student's t-test.
Conclusions
We hereby report the synthesis of chitosan-based nanoparticles
and their use as a carrier for selected Biginelli-based anticancer
compounds (THPMs). THPMs (A, B and C) were synthesized and
introduced for the rst time into the vehicles made of chitosan
(Ch). During the SEM analysis, two types of particles were
registered in the investigated systems, larger – with an average
diameter of 100  20 nm, and smaller – with an average



































































































View Article Onlineexamined using the MTT test in HeLa, LS-174, A549, MRC-5.
The obtained results indicate that all nanoparticulate systems
(A-Ch, B-Ch, and C-Ch) exhibit signicantly greater cytotoxicity
to the selected cancer cell lines than THPMs (A, B, and C). On
the other hand, the toxicity to healthy cell lines is signicantly
diminished compared to that of pure compounds. Therefore,
aer the treatment of HeLa cells with NPs systems during
a period of 24 hours, an early apoptosis was recorded. In
general, aer the treatment with NPs, the distribution of the cell
cycle was homogeneously affected. As far as the drug release
process is concerned, it can be observed that almost total drug
amount was released in three days, which suggest that the
prepared system enables relatively fast drug delivery. We have
designed a carrier suitable for the delivery of the Biginelli-based
drugs with a multifunctional effect: it allows selectivity and has
an improved anticancer activity followed by homogeneous cell
cycle distribution.Conflicts of interest
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